YahooAugust 10, 2026 at 11:41 AM NY25 days ago

Is IMCR Worth Buying as Kimmtrak Growth Meets a Premium Valuation?

Immunocore's Kimmtrak growth and late-stage catalysts strengthen its case, but a premium valuation and single-product risk raise the stakes.

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Yahoo

Companies in This Story